23.49
price up icon0.86%   0.20
after-market After Hours: 23.53 0.04 +0.17%
loading
Pfizer Inc stock is traded at $23.49, with a volume of 51.27M. It is up +0.86% in the last 24 hours and down -6.19% over the past month. Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.
See More
Previous Close:
$23.29
Open:
$23.3
24h Volume:
51.27M
Relative Volume:
1.23
Market Cap:
$133.55B
Revenue:
$62.46B
Net Income/Loss:
$7.88B
P/E Ratio:
17.02
EPS:
1.38
Net Cash Flow:
$11.22B
1W Performance:
-5.24%
1M Performance:
-6.19%
6M Performance:
-11.43%
1Y Performance:
-23.36%
1-Day Range:
Value
$23.11
$23.52
1-Week Range:
Value
$23.11
$24.73
52-Week Range:
Value
$20.91
$31.32

Pfizer Inc Stock (PFE) Company Profile

Name
Name
Pfizer Inc
Name
Phone
(212) 733-2323
Name
Address
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Name
Employee
81,000
Name
Twitter
@Pfizer
Name
Next Earnings Date
2025-02-04
Name
Latest SEC Filings
Name
PFE's Discussions on Twitter

Compare PFE with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Drug Manufacturers - General icon
PFE
Pfizer Inc
23.49 132.41B 62.46B 7.88B 11.22B 1.38
Drug Manufacturers - General icon
LLY
Lilly Eli Co
762.33 664.39B 49.00B 11.11B -1.27B 12.29
Drug Manufacturers - General icon
JNJ
Johnson Johnson
167.33 396.75B 90.63B 22.66B 16.40B 9.35
Drug Manufacturers - General icon
ABBV
Abbvie Inc
195.22 333.89B 58.33B 3.76B 15.39B 2.10
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
115.30 220.18B 55.19B 13.65B 16.81B 6.86
Drug Manufacturers - General icon
MRK
Merck Co Inc
79.29 196.16B 63.62B 16.41B 17.04B 6.49

Pfizer Inc Stock (PFE) Upgrades & Downgrades

Date Action Analyst Rating Change
Apr-22-25 Initiated Cantor Fitzgerald Neutral
Dec-10-24 Resumed BofA Securities Neutral
Nov-15-24 Initiated Wolfe Research Underperform
Oct-25-24 Resumed Citigroup Neutral
Oct-17-24 Initiated Bernstein Mkt Perform
Aug-07-24 Upgrade Daiwa Securities Neutral → Outperform
Mar-22-24 Downgrade Argus Buy → Hold
Feb-23-24 Initiated Guggenheim Buy
Jan-04-24 Downgrade TD Cowen Outperform → Market Perform
Oct-20-23 Resumed UBS Neutral
Oct-16-23 Upgrade Jefferies Hold → Buy
Jul-17-23 Reiterated JP Morgan Neutral
Jul-14-23 Initiated HSBC Securities Buy
Jun-29-23 Downgrade Credit Suisse Outperform → Neutral
May-11-23 Downgrade Daiwa Securities Outperform → Neutral
Mar-06-23 Initiated Jefferies Hold
Feb-07-23 Upgrade Daiwa Securities Neutral → Outperform
Jan-26-23 Downgrade UBS Buy → Neutral
Jan-17-23 Downgrade Wells Fargo Overweight → Equal Weight
Jan-04-23 Downgrade BofA Securities Buy → Neutral
Dec-13-22 Upgrade Goldman Neutral → Buy
Nov-18-22 Initiated Credit Suisse Outperform
May-23-22 Initiated SVB Leerink Mkt Perform
Apr-06-22 Resumed Morgan Stanley Equal-Weight
Jan-05-22 Upgrade BofA Securities Neutral → Buy
Jan-03-22 Reiterated Bernstein Mkt Perform
Dec-20-21 Reiterated Cowen Outperform
Dec-17-21 Initiated Goldman Neutral
Dec-13-21 Upgrade UBS Neutral → Buy
Dec-09-21 Initiated Wells Fargo Overweight
Nov-19-21 Initiated BMO Capital Markets Outperform
Jul-27-21 Resumed Truist Buy
May-06-21 Downgrade Mizuho Buy → Neutral
Apr-07-21 Resumed RBC Capital Mkts Sector Perform
Feb-04-21 Upgrade DZ Bank Hold → Buy
Dec-16-20 Downgrade RBC Capital Mkts Outperform → Sector Perform
Nov-19-20 Resumed Goldman Neutral
Nov-10-20 Resumed Bernstein Mkt Perform
Oct-12-20 Downgrade Atlantic Equities Overweight → Neutral
Sep-29-20 Initiated Berenberg Hold
Jun-16-20 Initiated SVB Leerink Mkt Perform
Feb-27-20 Initiated Barclays Equal Weight
Feb-27-20 Upgrade Standpoint Research Hold → Buy
Feb-06-20 Initiated Mizuho Buy
Jan-07-20 Initiated RBC Capital Mkts Outperform
Oct-17-19 Resumed BofA/Merrill Neutral
Jul-30-19 Downgrade BofA/Merrill Buy → Neutral
Jul-30-19 Downgrade Morgan Stanley Overweight → Equal-Weight
Jun-04-19 Resumed Morgan Stanley Overweight
Feb-20-19 Resumed Citigroup Neutral
Jan-31-19 Upgrade Argus Hold → Buy
Jan-31-19 Upgrade Credit Suisse Neutral → Outperform
Jan-23-19 Downgrade UBS Buy → Neutral
Dec-11-18 Downgrade JP Morgan Overweight → Neutral
Nov-01-18 Downgrade BMO Capital Markets Outperform → Market Perform
View All

Pfizer Inc Stock (PFE) Latest News

pulisher
06:22 AM

Pfizer's Q2 Earnings Loom: A Strategic Assessment for Investors - AInvest

06:22 AM
pulisher
04:53 AM

Pfizer CEO expected to attend Trump fundraiser after drug price cut demands - Anadolu Ajansı

04:53 AM
pulisher
04:23 AM

When You Look Back in a Few Years, You'll Wish You Had Bought This Unstoppable Artificial Intelligence (AI) Stock - The Motley Fool

04:23 AM
pulisher
12:11 PM

Pfizer CEO expected at Trump fundraiser - breakingthenews.net

12:11 PM
pulisher
Aug 01, 2025

Pfizer CEO attending $25 million fundraiser at Trump's golf club after president demands drug price cuts, sources say - CBS News

Aug 01, 2025
pulisher
Aug 01, 2025

Scooplet: The CEO of @Pfizer, Albert Bourla, is among those expected at the fundraiser President Trump is attending tonight, sources told @CBSNews. Trump yday sent letters to pharmaceutical companies, including Pfizer, demanding they lower U.S. drug pri - twitter.com

Aug 01, 2025
pulisher
Aug 01, 2025

Pfizer’s Abrysvo Study: A Closer Look at Safety in Pregnant Women and Infants - TipRanks

Aug 01, 2025
pulisher
Aug 01, 2025

Pfizer’s Ngenla Study: A Closer Look at Long-Term Safety for GHD Treatment - TipRanks

Aug 01, 2025
pulisher
Aug 01, 2025

Pfizer’s TALZENNA Study: A New Hope for Prostate Cancer Treatment? - TipRanks

Aug 01, 2025
pulisher
Aug 01, 2025

Pfizer’s Latest Clinical Study Update: Avelumab and Axitinib in Renal Cell Cancer - TipRanks

Aug 01, 2025
pulisher
Aug 01, 2025

Pfizer, BioNTech lose UK appeal to overturn Moderna's COVID vaccine patent win - Reuters

Aug 01, 2025
pulisher
Aug 01, 2025

Pfizer’s New Study on PF-07934040: A Potential Game-Changer in Cancer Treatment? - TipRanks

Aug 01, 2025
pulisher
Aug 01, 2025

Pfizer’s New Study on Abrocitinib: A Potential Breakthrough for Pediatric Eczema - TipRanks

Aug 01, 2025
pulisher
Aug 01, 2025

Pfizer’s Ongoing Safety Study of BNT162b2 in Korea: Key Insights for Investors - TipRanks

Aug 01, 2025
pulisher
Aug 01, 2025

Pfizer’s Phase 3 Study: Evaluating Co-administration of RSV and Shingles Vaccines - TipRanks

Aug 01, 2025
pulisher
Aug 01, 2025

Moderna Fights Off Pfizer Challenge To Surviving mRNA IP - Law360

Aug 01, 2025
pulisher
Aug 01, 2025

Moderna Wins UK Patent Battle Against Pfizer and BioNTech - BioSpace

Aug 01, 2025
pulisher
Aug 01, 2025

Buy, Sell or Hold Pfizer Stock? Key Tips Ahead of Q2 Earnings - Nasdaq

Aug 01, 2025
pulisher
Aug 01, 2025

Pfizer/BioNTech lose appeal to reverse Moderna’s COVID vaccine patent win in U.K. - Seeking Alpha

Aug 01, 2025
pulisher
Aug 01, 2025

How To Trade Pfizer Stock Ahead of Its Upcoming Earnings? - Trefis

Aug 01, 2025
pulisher
Aug 01, 2025

Should You Buy Pfizer (PFE) Stock Before August 5? Here's What History Says - MSN

Aug 01, 2025
pulisher
Aug 01, 2025

Pfizer losses appeal in Moderna patent case - breakingthenews.net

Aug 01, 2025
pulisher
Aug 01, 2025

UK Court of Appeal Confirms Moderna’s EP'949 Patent is Valid and Infringed by Pfizer/BioNTech - The Daily Reflector

Aug 01, 2025
pulisher
Aug 01, 2025

Moderna Secures Major Patent Victory: UK Court Rules Pfizer Infringed COVID-19 Vaccine Technology - Stock Titan

Aug 01, 2025
pulisher
Jul 31, 2025

Pfizer (PFE) Dips More Than Broader Market: What You Should Know - Yahoo Finance

Jul 31, 2025
pulisher
Jul 31, 2025

Trump Demands Pharma Companies Slash US Drug Prices in Letter - Bloomberg

Jul 31, 2025
pulisher
Jul 31, 2025

Trump demands largest pharma companies slash US drug prices - Yahoo Finance

Jul 31, 2025
pulisher
Jul 31, 2025

Purdue and Gleaners Food Bank to Open Pharmacy, Concerns Over Eli Lilly and Pfizer Relationship, IU Researchers get Top Awards, Ground Breaking for New Subsidized Housing - WFYI

Jul 31, 2025
pulisher
Jul 31, 2025

Pfizer’s Promising Phase 2 Study on Advanced Breast Cancer Treatment - TipRanks

Jul 31, 2025
pulisher
Jul 31, 2025

Pfizer’s Promising Phase 3 Study on NSCLC Treatment: A Market Game-Changer? - TipRanks

Jul 31, 2025
pulisher
Jul 31, 2025

Pfizer’s New Hope: PF-08046031 Study in Advanced Melanoma and Solid Tumors - TipRanks

Jul 31, 2025
pulisher
Jul 31, 2025

Pfizer’s MagnetisMM-32 Study: A New Hope for Multiple Myeloma Treatment - TipRanks

Jul 31, 2025
pulisher
Jul 31, 2025

Pfizer’s Latest Study on HER2-positive Breast Cancer: A Real-World Perspective - TipRanks

Jul 31, 2025
pulisher
Jul 31, 2025

Pfizer’s COVID-19 Vaccine Study: Key Insights and Market Impact - TipRanks

Jul 31, 2025
pulisher
Jul 31, 2025

Pfizer and Astellas Advance Prostate Cancer Study with Promising Drug Combo - TipRanks

Jul 31, 2025
pulisher
Jul 31, 2025

Pfizer’s Phase 3 Study on Elranatamab vs. Lenalidomide: A Potential Game-Changer in Multiple Myeloma Treatment - TipRanks

Jul 31, 2025
pulisher
Jul 31, 2025

Pfizer and Genmab’s Tivdak Study: Assessing Ocular Safety in Cervical Cancer Treatment - TipRanks

Jul 31, 2025
pulisher
Jul 31, 2025

Pfizer’s TALZENNA Study: A Potential Game-Changer in Breast Cancer Treatment - TipRanks

Jul 31, 2025
pulisher
Jul 31, 2025

Pfizer’s Sisunatovir Study: A Promising Step in RSV Treatment - TipRanks

Jul 31, 2025
pulisher
Jul 31, 2025

Pfizer’s Elranatamab Study: A Real-World Insight into Multiple Myeloma Treatment - TipRanks

Jul 31, 2025
pulisher
Jul 31, 2025

Stay Ahead of the Game With Pfizer (PFE) Q2 Earnings: Wall Street's Insights on Key Metrics - Yahoo Finance

Jul 31, 2025
pulisher
Jul 31, 2025

Pfizer: Lack Of Enthusiasm Shouldn't Surprise You - Seeking Alpha

Jul 31, 2025
pulisher
Jul 31, 2025

Where Will Pfizer (PFE) Be in 5 Years? - AOL.com

Jul 31, 2025
pulisher
Jul 31, 2025

Bank of America Securities Maintains a Hold on Pfizer (PFE) - Insider Monkey

Jul 31, 2025
pulisher
Jul 30, 2025

Pfizer Shares Plunge 2.02% Amid Vaccine Advances and Cancer Deal, Ranked 118th in $860M Trading Volume - AInvest

Jul 30, 2025
pulisher
Jul 30, 2025

Pfizer’s (PFE) Breakthrough Medicines Power its Dividend Stability - Insider Monkey

Jul 30, 2025
pulisher
Jul 30, 2025

Pfizer and Astellas Pharma’s Promising mCRPC Study Update - TipRanks

Jul 30, 2025
pulisher
Jul 30, 2025

Pfizer’s Gene Therapy Study for Duchenne Muscular Dystrophy: A Market Game-Changer? - TipRanks

Jul 30, 2025
pulisher
Jul 30, 2025

Pfizer’s Phase 3 Study on Avelumab and Axitinib in Renal Cancer: A Market Game-Changer? - TipRanks

Jul 30, 2025
pulisher
Jul 30, 2025

Pfizer’s New Study on Abrocitinib: A Potential Game-Changer for Pediatric Eczema - TipRanks

Jul 30, 2025
pulisher
Jul 30, 2025

Pfizer’s Latest Clinical Study: A Potential Game-Changer in Cancer Treatment - TipRanks

Jul 30, 2025

Pfizer Inc Stock (PFE) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$113.18
price up icon 0.79%
drug_manufacturers_general SNY
$46.75
price up icon 2.43%
$296.88
price up icon 0.60%
drug_manufacturers_general NVO
$48.19
price up icon 2.38%
drug_manufacturers_general MRK
$79.29
price up icon 1.50%
Cap:     |  Volume (24h):